« Return to News | CROs/Service Providers | Miscellaneous

Cost Cuts Start to Pay Off for Kendle

Thursday, May 6, 2010 07:27 AM

Kendle’s revenues dropped 17% in the first quarter, but cost-cutting measures implemented early in the year helped the contract research organization’s Q1 net income grow 35%. First-quarter 2010 profits increased to $1.2 million, or $0.08 per diluted share, in the first quarter 2010, up from $886,000, or $0.06 per diluted share, in 2009. Net revenues totaled $90.2 million, compared with $108.1 million in Q1 2009.

Operating income was still down significantly from last year, with income for operations for the quarter at $4.3 million, compared with $8.1 million in 2009.

"While Kendle has had a particularly challenging first quarter, we saw improvement throughout the period and up until today," said chairman and CEO Candace Kendle. "Our customers would appear to be at the end of their pipeline realignments and merger-related disruptions and are settling into selection of CRO partners. Cost efficiency remains a top priority for our customers, and outsourcing is a key strategy in achieving it. We are encouraged about the latter half of 2010 and into 2011."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.